drugset / Trial / NCT04621565

Hydrocortisone Use During Peri-operation for Pituitary Adenomas

NCT04621565

RandomizedParallel-groupTriple-blindPrevention

Summary

The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.

Timeline

Start
2020-11-01
Primary completion
2022-07
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrocortisone Other / unclassified 20 mg Intravenous